Trait: type 2 diabetes mellitus

Trait Information
Identifier MONDO_0005148
Description A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity. [NCIT: P378]
Trait categories
Digestive system disorder
Metabolic disorder
Synonyms 30 synonyms
  • NIDDM
  • T2DM - type 2 diabetes mellitus
  • adult onset diabetes
  • adult-onset diabetes
  • diabetes mellitis type 2
  • diabetes mellitis type II
  • diabetes mellitus, non-insulin-dependent, susceptibility to
  • diabetes mellitus, noninsulin-dependent
  • diabetes mellitus, noninsulin-dependent, 2
  • diabetes mellitus, noninsulin-dependent, association with
  • diabetes mellitus, noninsulin-dependent, late onset
  • diabetes mellitus, noninsulin-dependent, susceptibility to
  • diabetes mellitus, type 2
  • diabetes mellitus, type 2, susceptibility to
  • diabetes mellitus, type II
  • diabetes mellitus, type II, susceptibility to
  • diabetes, type 2
  • hypertension, insulin resistance-related, susceptibility to
  • insulin resistance, severe, digenic
  • non-insulin dependent diabetes
  • non-insulin dependent diabetes mellitus
  • non-insulin-dependent diabetes mellitus
  • noninsulin dependent diabetes
  • noninsulin-dependent diabetes mellitus
  • type 2 diabetes
  • type 2 diabetes mellitus
  • type 2 diabetes mellitus non-insulin dependent
  • type 2 diabetes mellitus, susceptibility to
  • type II diabetes
  • type II diabetes mellitus
Mapped terms 8 mapped terms
  • DOID:9352
  • EFO:0001360
  • KEGG:04930
  • MESH:D003924
  • NCIT:C26747
  • OMIM:125853
  • SCTID:44054006
  • UMLS:CN244395

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution Scoring File (FTP Link)
PGS000014
(GPS_T2D)
 PGP000006 |
Khera AV et al. Nat Genet (2018)
 Type 2 diabetes type 2 diabetes mellitus 6,917,436
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000014/ScoringFiles/PGS000014.txt.gz - Check Terms/Licenses
PGS000020
(dGRS1000)
 PGP000010 |
Läll K et al. Genet Med (2016)
 Type 2 diabetes type 2 diabetes mellitus 7,502
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000020/ScoringFiles/PGS000020.txt.gz
PGS000031
(GRSt)
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Type 2 diabetes type 2 diabetes mellitus 62
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000031/ScoringFiles/PGS000031.txt.gz
PGS000032
(GRSB)
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Type 2 diabetes (based on SNPs involved in β-cell function) type 2 diabetes mellitus 20
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000032/ScoringFiles/PGS000032.txt.gz
PGS000033
(GRSIR)
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Type 2 diabetes (based on SNPs involved in insulin resistance) type 2 diabetes mellitus 10
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000033/ScoringFiles/PGS000033.txt.gz
PGS000036
(gePS_T2D)
 PGP000023 |
Mahajan A et al. Nat Genet (2018)
 Type 2 diabetes type 2 diabetes mellitus 171,249
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000036/ScoringFiles/PGS000036.txt.gz
PGS000125
(Qi_T2D_2017)
 PGP000062 |
Qi Q et al. Diabetes (2017)
 Type 2 Diabetes type 2 diabetes mellitus 80
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000125/ScoringFiles/PGS000125.txt.gz
PGS000330
(PRS_T2D)
 PGP000100 |
Mars N et al. Nat Med (2020)
 Type 2 diabetes type 2 diabetes mellitus 6,437,380
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000330/ScoringFiles/PGS000330.txt.gz
PGS000712
(T2D_HbA1c_39)
 PGP000128 |
Sinnott-Armstrong N et al. Nat Genet (2021)
 T2D (cases vs HbA1c filtered controls) type 2 diabetes mellitus 183,695
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000712/ScoringFiles/PGS000712.txt.gz - Check Terms/Licenses
PGS000713
(T2D)
 PGP000128 |
Sinnott-Armstrong N et al. Nat Genet (2021)
 T2D type 2 diabetes mellitus 183,830
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000713/ScoringFiles/PGS000713.txt.gz - Check Terms/Licenses
PGS000729
(T2D_PGS)
 PGP000137 |
Ritchie SC et al. Nat Metab (2021)
 Type 2 diabetes type 2 diabetes mellitus 2,017,388
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000729/ScoringFiles/PGS000729.txt.gz
PGS000804
(GRS582_T2Dmulti)
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Type 2 diabetes type 2 diabetes mellitus 582
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000804/ScoringFiles/PGS000804.txt.gz - Check Terms/Licenses
PGS000805
(GRS582_T2Deur)
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Type 2 diabetes type 2 diabetes mellitus 582
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000805/ScoringFiles/PGS000805.txt.gz - Check Terms/Licenses
PGS000806
(GRS582_T2Dafr)
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Type 2 diabetes type 2 diabetes mellitus 582
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000806/ScoringFiles/PGS000806.txt.gz - Check Terms/Licenses
PGS000807
(GRS582_T2Dasn)
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Type 2 diabetes type 2 diabetes mellitus 582
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000807/ScoringFiles/PGS000807.txt.gz - Check Terms/Licenses
PGS000808
(GRS582_T2Dhis)
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Type 2 diabetes type 2 diabetes mellitus 582
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000808/ScoringFiles/PGS000808.txt.gz - Check Terms/Licenses
PGS000832
(T2D-GRS)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes type 2 diabetes mellitus 384
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000832/ScoringFiles/PGS000832.txt.gz
PGS000848
(T2D_Adiposity)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with adiposity) type 2 diabetes mellitus 6
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000848/ScoringFiles/PGS000848.txt.gz
PGS000849
(T2D_Impaired_Lipids)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with impaired lipids) type 2 diabetes mellitus 3
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000849/ScoringFiles/PGS000849.txt.gz
PGS000850
(T2D_Insulin_Action)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with insulin action) type 2 diabetes mellitus 16
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000850/ScoringFiles/PGS000850.txt.gz
PGS000851
(T2D_Insulin_Action_Secretion)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with insulin action/secretion) type 2 diabetes mellitus 37
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000851/ScoringFiles/PGS000851.txt.gz
PGS000852
(T2D_Insulin_Secretion_1)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with insulin secretion) type 2 diabetes mellitus 8
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000852/ScoringFiles/PGS000852.txt.gz
PGS000853
(T2D_Insulin_Secretion_2)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with insulin secretion) type 2 diabetes mellitus 21
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000853/ScoringFiles/PGS000853.txt.gz
PGS000854
(T2D_BetaCell)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with beta cell function) type 2 diabetes mellitus 27
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000854/ScoringFiles/PGS000854.txt.gz
PGS000855
(T2D_Lipodystrophy)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with lipodystrophy) type 2 diabetes mellitus 18
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000855/ScoringFiles/PGS000855.txt.gz
PGS000856
(T2D_LiverLipids)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with liver lipids) type 2 diabetes mellitus 3
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000856/ScoringFiles/PGS000856.txt.gz
PGS000857
(T2D_Obesity)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with obesity) type 2 diabetes mellitus 4
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000857/ScoringFiles/PGS000857.txt.gz
PGS000858
(T2D_Proinsulin)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes (based on SNPs associated with proinsulin levels) type 2 diabetes mellitus 6
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000858/ScoringFiles/PGS000858.txt.gz
PGS000864
(T2D-gPRS)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Type 2 diabetes type 2 diabetes mellitus 389,243
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000864/ScoringFiles/PGS000864.txt.gz
PGS000868
(T2D_221)
 PGP000214 |
Aksit MA et al. J Clin Endocrinol Metab (2020)
 Type II diabetes type 2 diabetes mellitus 221
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000868/ScoringFiles/PGS000868.txt.gz
PGS001294
(GBE_HC649)
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Non-insulin-dependent diabetes (time-to-event) type 2 diabetes mellitus 3,496
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001294/ScoringFiles/PGS001294.txt.gz
PGS001295
(GBE_HC165)
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Type 2 diabetes type 2 diabetes mellitus 385
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001295/ScoringFiles/PGS001295.txt.gz
PGS001357
(T2D_AnnoPred_PRS)
 PGP000252 |
Ye Y et al. Circ Genom Precis Med (2021)
 Type 2 diabetes type 2 diabetes mellitus 2,996,761
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001357/ScoringFiles/PGS001357.txt.gz
PGS001781
(T2D_PRSCS)
 PGP000261 |
Tamlander M et al. Commun Biol (2022)
 Type 2 diabetes type 2 diabetes mellitus 1,091,673
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001781/ScoringFiles/PGS001781.txt.gz
PGS001818
(portability-PLR_250.2)
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Type 2 diabetes type 2 diabetes mellitus 30,745
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001818/ScoringFiles/PGS001818.txt.gz
PGS002026
(portability-ldpred2_250.2)
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Type 2 diabetes type 2 diabetes mellitus 830,783
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002026/ScoringFiles/PGS002026.txt.gz
PGS002243
(ldpred_t2d)
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Type 2 diabetes type 2 diabetes mellitus 6,431,973
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002243/ScoringFiles/PGS002243.txt.gz
PGS002277
(pPS_Insulin_secretion_1)
 PGP000305 |
Siddiqui MK et al. Diabetologia (2022)
 Type 2 diabetes (based on SNPs associated with insulin secretion) type 2 diabetes mellitus 8
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002277/ScoringFiles/PGS002277.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		Evaluated Score PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000023 PGS000014
(GPS_T2D)
 PSS000017|
European Ancestry|
288,978 individuals
 PGP000006 |
Khera AV et al. Nat Genet (2018)
 Reported Trait: Type 2 diabetes — AUROC: 0.73 [0.72, 0.73] Nagelkerke’s R2 (estimate of variance explained by the PGS after covariate adjustment): 0.029 age; sex; Ancestry PC 1-4; genotyping chip —
PPM002477 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes — C-index: 0.709 [0.696, 0.722] Hazard ratio (HR, top 10% vs. remaining 90%): 2.0 [1.73, 2.31] Sex, age, principal components, assessment center —
PPM002478 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes in males — C-index: 0.68 [0.663, 0.697] — Age, principal components and assessment center —
PPM002479 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes in females — C-index: 0.705 [0.682, 0.728] — Age, principal components and assessment center —
PPM002480 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes — C-index: 0.776 [0.764, 0.788] — Sex, age, principal components, assessment center, polyexposure score —
PPM002481 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes — C-index: 0.844 [0.834, 0.854] — Sex, age, principal components, assessment center, clinical risk score —
PPM002482 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes — C-index: 0.855 [0.845, 0.865] — Sex, age, principal components, assessment center, polyexposure socre, clinical risk score —
PPM002483 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes in females — C-index: 0.786 [0.765, 0.807] — Age, principal components, assessment center, polyexposure score —
PPM002485 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes in females — C-index: 0.859 [0.842, 0.876] — Sex, age, principal components, assessment center, clinical risk score —
PPM002486 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes in males — C-index: 0.749 [0.734, 0.764] — Age, principal components, assessment center, polyexposure score —
PPM002487 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes in males — C-index: 0.821 [0.808, 0.834] — Age, principal components, assessment center, polyexposure socre, clinical risk score —
PPM002488 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes in males — C-index: 0.834 [0.821, 0.847] — Sex, age, principal components, assessment center, clinical risk score —
PPM002484 PGS000014
(GPS_T2D)
 PSS001117|
European Ancestry|
68,229 individuals
 PGP000218 |
He Y et al. Diabetes Care (2021)
|Ext.		 Reported Trait: Incident type II diabetes in females — C-index: 0.869 [0.853, 0.885] — Age, principal components, assessment center, polyexposure socre, clinical risk score —
PPM000040 PGS000020
(dGRS1000)
 PSS000025|
European Ancestry|
6,280 individuals
 PGP000010 |
Läll K et al. Genet Med (2016)
 Reported Trait: Incident type 2 diabetes HR: 1.48 [1.32, 1.66] C-index: 0.79 [0.771, 0.812] — BMI category, smoking level, waist-to-hip ratio, waist circumference, physical activity level, history of high blood glucose, fruit and vegetable consumption, and sex. Cox age-as-time-scale
PPM000062 PGS000031
(GRSt)
 PSS000044|
European Ancestry|
3,471 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 1.06 [1.04, 1.08] C-index: 0.906 [0.892, 0.92] — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model"
PPM000063 PGS000031
(GRSt)
 PSS000043|
European Ancestry|
1,650 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 1.06 [1.02, 1.1] C-index: 0.853 [0.81, 0.896] — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model"
PPM000064 PGS000031
(GRSt)
 PSS000042|
African Ancestry|
820 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 1.05 [1.0, 1.09] C-index: 0.771 [0.727, 0.814] — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model", SNPs were not weighted by their effect size as the betas were measure in Europeans
PPM000065 PGS000032
(GRSB)
 PSS000044|
European Ancestry|
3,471 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 1.1 [1.06, 1.14] — — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model"
PPM000066 PGS000032
(GRSB)
 PSS000043|
European Ancestry|
1,650 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 1.09 [1.02, 1.17] — — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model"
PPM000067 PGS000032
(GRSB)
 PSS000042|
African Ancestry|
820 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 1.06 [0.99, 1.15] — — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model", SNPs were not weighted by their effect size as the betas were measure in Europeans
PPM002415 PGS000032
(GRSB)
 PSS001092|
Ancestry Not Reported|
5,740 individuals
 PGP000214 |
Aksit MA et al. J Clin Endocrinol Metab (2020)
|Ext.		 Reported Trait: Cystic-fibrosis related diabetes onset HR: 1.192 — — PCs(1-4), site of recruitment —
PPM000068 PGS000033
(GRSIR)
 PSS000044|
European Ancestry|
3,471 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 0.98 [0.93, 1.04] — — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model"
PPM000069 PGS000033
(GRSIR)
 PSS000043|
European Ancestry|
1,650 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 1.01 [0.91, 1.12] — — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model"
PPM000070 PGS000033
(GRSIR)
 PSS000042|
African Ancestry|
820 individuals
 PGP000020 |
Vassy JL et al. Diabetes (2014)
 Reported Trait: Incident type 2 diabetes cases HR: 1.06 [0.99, 1.15] — — age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels Results from the "Clinical model", SNPs were not weighted by their effect size as the betas were measure in Europeans
PPM000080 PGS000036
(gePS_T2D)
 PSS000054|
European Ancestry|
324,870 individuals
 PGP000024 |
Udler MS et al. Endocr Rev (2019)
|Ext.		 Reported Trait: Type 2 diabetes — AUROC: 0.66 — genotyping array, first 6 PCs of ancestry —
PPM000081 PGS000036
(gePS_T2D)
 PSS000054|
European Ancestry|
324,870 individuals
 PGP000024 |
Udler MS et al. Endocr Rev (2019)
|Ext.		 Reported Trait: Type 2 diabetes — AUROC: 0.73 — age, sex, genotyping array, first 6 PCs of ancestry —
PPM000404 PGS000125
(Qi_T2D_2017)
 PSS000232|
Hispanic or Latin American Ancestry|
7,746 individuals
 PGP000062 |
Qi Q et al. Diabetes (2017)
 Reported Trait: Type 2 Diabetes — — OR (Odds Ratio, per risk allele): 1.07 [1.06, 1.08] center, age, sex, 5 PCs of ancestry Covariance matrices corresponding to genetic relatedness (kinship), household, and census block group were included as random effects in the mixed model analysis
PPM000897 PGS000330
(PRS_T2D)
 PSS000441|
European Ancestry|
21,030 individuals
 PGP000100 |
Mars N et al. Nat Med (2020)
 Reported Trait: Incident type 2 diabetes — C-index: 0.845 — age, sex, BMI, history of stroke or CHD, parental history of diabetes, SBP, DBP, HDL, triglycerides, FINRISK cohort, genotyping array/batch, 10 ancestry PCs 10-year risk
PPM000892 PGS000330
(PRS_T2D)
 PSS000441|
European Ancestry|
21,030 individuals
 PGP000100 |
Mars N et al. Nat Med (2020)
 Reported Trait: Incident type 2 diabetes HR: 1.7 [1.63, 1.78] C-index: 0.763 — age, sex, FINRISK cohort, genotyping array/batch, 10 ancestry PCs 10-year risk
PPM000887 PGS000330
(PRS_T2D)
 PSS000448|
European Ancestry|
135,300 individuals
 PGP000100 |
Mars N et al. Nat Med (2020)
 Reported Trait: Type 2 diabetes (incident and prevalent cases) HR: 1.74 [1.72, 1.77] — — genotyping array/batch, 10 ancestry PCs, stratified by sex —
PPM001604 PGS000712
(T2D_HbA1c_39)
 PSS000755|
European Ancestry|
87,413 individuals
 PGP000128 |
Sinnott-Armstrong N et al. Nat Genet (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.68713 — Age, sex, PCs(1-10) —
PPM001605 PGS000713
(T2D)
 PSS000754|
European Ancestry|
87,413 individuals
 PGP000128 |
Sinnott-Armstrong N et al. Nat Genet (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.688 — Age, sex, PCs(1-10) —
PPM001615 PGS000713
(T2D)
 PSS000756|
European Ancestry|
135,300 individuals
 PGP000128 |
Sinnott-Armstrong N et al. Nat Genet (2021)
 Reported Trait: Type 2 diabetes HR: 1.49 [1.47, 1.51] C-index: 0.669 — Age as time scale, sex, batch, PCs(1-10) —
PPM001667 PGS000729
(T2D_PGS)
 PSS000869|
European Ancestry|
3,087 individuals
 PGP000137 |
Ritchie SC et al. Nat Metab (2021)
 Reported Trait: Incident type 2 diabetes HR: 2.0 [1.36, 2.94] — — age, sex, 10 genetic PCs —
PPM002117 PGS000804
(GRS582_T2Dmulti)
 PSS001044|
African Ancestry|
15,609 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.568 [0.5588, 0.5772] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002119 PGS000804
(GRS582_T2Dmulti)
 PSS001046|
European Ancestry|
423,729 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.825 [0.8222, 0.8279] Odds Ratio (OR, top 10% vs middle 20%): 2.94 [2.8, 3.08] Age, sex, body mass index, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002121 PGS000804
(GRS582_T2Dmulti)
 PSS001046|
European Ancestry|
423,729 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6586 [0.6547, 0.6624] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002123 PGS000804
(GRS582_T2Dmulti)
 PSS001047|
Hispanic or Latin American Ancestry|
20,486 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.7293 [0.721, 0.7376] Odds Ratio (OR, top 10% vs middle 20%): 2.39 [2.1, 2.73] Age, sex, body mass index, study, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002125 PGS000804
(GRS582_T2Dmulti)
 PSS001047|
Hispanic or Latin American Ancestry|
20,486 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6249 [0.6156, 0.6342] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002127 PGS000804
(GRS582_T2Dmulti)
 PSS001045|
Additional Asian Ancestries|
4,576 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.8411 [0.8298, 0.8523] Odds Ratio (OR, top 10% vs middle 20%): 3.08 [2.4, 3.95] Age, sex, body mass index, study, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002129 PGS000804
(GRS582_T2Dmulti)
 PSS001045|
Additional Asian Ancestries|
4,576 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6263 [0.6101, 0.6425] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002131 PGS000804
(GRS582_T2Dmulti)
 PSS001048|
Additional Diverse Ancestries|
3,551 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.7989 [0.7845, 0.8133] Odds Ratio (OR, top 10% vs middle 20%): 2.02 [1.54, 2.65] Age, sex, body mass index, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002133 PGS000804
(GRS582_T2Dmulti)
 PSS001048|
Additional Diverse Ancestries|
3,551 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6214 [0.603, 0.6399] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002115 PGS000804
(GRS582_T2Dmulti)
 PSS001044|
African Ancestry|
15,609 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6701 [0.6615, 0.6788] Odds Ratio (OR, top 10% vs middle 20%): 1.57 [1.39, 1.77] Age, sex, body mass index, study, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002120 PGS000805
(GRS582_T2Deur)
 PSS001046|
European Ancestry|
423,729 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.8253 [0.8224, 0.8281] Odds Ratio (OR, top 10% vs middle 20%): 2.95 [2.81, 3.1] Age, sex, body mass index, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002122 PGS000805
(GRS582_T2Deur)
 PSS001046|
European Ancestry|
423,729 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6593 [0.6555, 0.6632] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002134 PGS000805
(GRS582_T2Deur)
 PSS001048|
Additional Diverse Ancestries|
3,551 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6213 [0.6029, 0.6397] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. Population-specific weights were not available for indiviuals of an Oceanian ancestry (Native Hawaiian). Therefore, GRS582_T2Deur was utilised to predict type 2 diabetes in individuals of an Oceanian ancestry.
PPM002132 PGS000805
(GRS582_T2Deur)
 PSS001048|
Additional Diverse Ancestries|
3,551 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.7985 [0.7842, 0.8129] Odds Ratio (OR, top 10% vs middle 20%): 2.13 [1.63, 2.79] Age, sex, body mass index, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. Population-specific weights were not available for indiviuals of an Oceanian ancestry (Native Hawaiian). Therefore, GRS582_T2Deur was utilised to predict type 2 diabetes in individuals of an Oceanian ancestry.
PPM002116 PGS000806
(GRS582_T2Dafr)
 PSS001044|
African Ancestry|
15,609 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6656 [0.6569, 0.6743] Odds Ratio (OR, top 10% vs middle 20%): 1.53 [1.36, 1.73] Age, sex, body mass index, study, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002118 PGS000806
(GRS582_T2Dafr)
 PSS001044|
African Ancestry|
15,609 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.5592 [0.5499, 0.5684] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002128 PGS000807
(GRS582_T2Dasn)
 PSS001045|
Additional Asian Ancestries|
4,576 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.8388 [0.8274, 0.8502] Odds Ratio (OR, top 10% vs middle 20%): 2.84 [2.21, 3.65] Age, sex, body mass index, study, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002130 PGS000807
(GRS582_T2Dasn)
 PSS001045|
Additional Asian Ancestries|
4,576 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6161 [0.5998, 0.6324] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002135 PGS000807
(GRS582_T2Dasn)
 PSS001048|
Additional Diverse Ancestries|
3,551 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.7909 [0.7763, 0.8056] Odds Ratio (OR, top 10% vs middle 20%): 1.62 [1.23, 2.14] Age, sex, body mass index, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. Population-specific weights were not available for indiviuals of an Oceanian ancestry (Native Hawaiian). Therefore, GRS582_T2Dasn was utilised to predict type 2 diabetes in individuals of an Oceanian ancestry.
PPM002136 PGS000807
(GRS582_T2Dasn)
 PSS001048|
Additional Diverse Ancestries|
3,551 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.5768 [0.558, 0.5956] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. Population-specific weights were not available for indiviuals of an Oceanian ancestry (Native Hawaiian). Therefore, GRS582_T2Dasn was utilised to predict type 2 diabetes in individuals of an Oceanian ancestry.
PPM002124 PGS000808
(GRS582_T2Dhis)
 PSS001047|
Hispanic or Latin American Ancestry|
20,486 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.7202 [0.7118, 0.7286] Odds Ratio (OR, top 10% vs middle 20%): 2.04 [1.79, 2.32] Age, sex, body mass index, study, PCs(1-10) Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002126 PGS000808
(GRS582_T2Dhis)
 PSS001047|
Hispanic or Latin American Ancestry|
20,486 individuals
 PGP000193 |
Polfus LM et al. HGG Adv (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6098 [0.6004, 0.6192] — — Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts.
PPM002240 PGS000832
(T2D-GRS)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.24 [1.16, 1.34] — — PC1-10 —
PPM002242 PGS000832
(T2D-GRS)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.77 [1.67, 1.88] — — PC1-10 —
PPM002239 PGS000832
(T2D-GRS)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.96 [1.81, 2.12] — — PC1-10 —
PPM002238 PGS000832
(T2D-GRS)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.28 [1.16, 1.42] — — PC1-10 —
PPM002241 PGS000832
(T2D-GRS)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.73 [1.61, 1.86] — — PC1-10 —
PPM002323 PGS000848
(T2D_Adiposity)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.11 [1.0, 1.23] — — PC1-10 —
PPM002324 PGS000848
(T2D_Adiposity)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.1 [1.02, 1.18] — — PC1-10 —
PPM002325 PGS000848
(T2D_Adiposity)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.11 [1.03, 1.19] — — PC1-10 —
PPM002326 PGS000848
(T2D_Adiposity)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.2 [1.12, 1.28] — — PC1-10 —
PPM002327 PGS000848
(T2D_Adiposity)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.06 [1.0, 1.12] — — PC1-10 —
PPM002329 PGS000849
(T2D_Impaired_Lipids)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.07 [1.0, 1.15] — — PC1-10 —
PPM002330 PGS000849
(T2D_Impaired_Lipids)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.09 [1.01, 1.17] — — PC1-10 —
PPM002331 PGS000849
(T2D_Impaired_Lipids)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.0 [0.93, 1.07] — — PC1-10 —
PPM002332 PGS000849
(T2D_Impaired_Lipids)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.06 [1.0, 1.12] — — PC1-10 —
PPM002328 PGS000849
(T2D_Impaired_Lipids)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.08 [0.97, 1.2] — — PC1-10 —
PPM002333 PGS000850
(T2D_Insulin_Action)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.08 [0.98, 1.2] — — PC1-10 —
PPM002334 PGS000850
(T2D_Insulin_Action)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.17 [1.09, 1.25] — — PC1-10 —
PPM002335 PGS000850
(T2D_Insulin_Action)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.17 [1.09, 1.26] — — PC1-10 —
PPM002337 PGS000850
(T2D_Insulin_Action)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.16 [1.1, 1.23] — — PC1-10 —
PPM002336 PGS000850
(T2D_Insulin_Action)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.14 [1.07, 1.22] — — PC1-10 —
PPM002338 PGS000851
(T2D_Insulin_Action_Secretion)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.24 [1.12, 1.37] — — PC1-10 —
PPM002339 PGS000851
(T2D_Insulin_Action_Secretion)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.23 [1.15, 1.32] — — PC1-10 —
PPM002340 PGS000851
(T2D_Insulin_Action_Secretion)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.04 [0.97, 1.11] — — PC1-10 —
PPM002341 PGS000851
(T2D_Insulin_Action_Secretion)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.19 [1.12, 1.28] — — PC1-10 —
PPM002342 PGS000851
(T2D_Insulin_Action_Secretion)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.19 [1.13, 1.26] — — PC1-10 —
PPM002343 PGS000852
(T2D_Insulin_Secretion_1)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.01 [0.91, 1.12] — — PC1-10 —
PPM002344 PGS000852
(T2D_Insulin_Secretion_1)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.31 [1.22, 1.41] — — PC1-10 —
PPM002345 PGS000852
(T2D_Insulin_Secretion_1)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.04 [0.97, 1.12] — — PC1-10 —
PPM002347 PGS000852
(T2D_Insulin_Secretion_1)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.29 [1.22, 1.37] — — PC1-10 —
PPM002346 PGS000852
(T2D_Insulin_Secretion_1)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.26 [1.18, 1.35] — — PC1-10 —
PPM002348 PGS000853
(T2D_Insulin_Secretion_2)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 0.99 [0.9, 1.1] — — PC1-10 —
PPM002349 PGS000853
(T2D_Insulin_Secretion_2)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.26 [1.18, 1.36] — — PC1-10 —
PPM002350 PGS000853
(T2D_Insulin_Secretion_2)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.02 [0.95, 1.09] — — PC1-10 —
PPM002351 PGS000853
(T2D_Insulin_Secretion_2)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.18 [1.11, 1.27] — — PC1-10 —
PPM002352 PGS000853
(T2D_Insulin_Secretion_2)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.23 [1.17, 1.3] — — PC1-10 —
PPM002353 PGS000854
(T2D_BetaCell)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.0 [0.91, 1.11] — — PC1-10 —
PPM002354 PGS000854
(T2D_BetaCell)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.32 [1.23, 1.42] — — PC1-10 —
PPM002355 PGS000854
(T2D_BetaCell)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.01 [0.94, 1.08] — — PC1-10 —
PPM002357 PGS000854
(T2D_BetaCell)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.27 [1.2, 1.34] — — PC1-10 —
PPM002356 PGS000854
(T2D_BetaCell)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.21 [1.13, 1.3] — — PC1-10 —
PPM002358 PGS000855
(T2D_Lipodystrophy)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.12 [1.01, 1.25] — — PC1-10 —
PPM002359 PGS000855
(T2D_Lipodystrophy)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.23 [1.15, 1.33] — — PC1-10 —
PPM002360 PGS000855
(T2D_Lipodystrophy)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.15 [1.07, 1.24] — — PC1-10 —
PPM002361 PGS000855
(T2D_Lipodystrophy)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.14 [1.06, 1.22] — — PC1-10 —
PPM002362 PGS000855
(T2D_Lipodystrophy)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.18 [1.11, 1.24] — — PC1-10 —
PPM002363 PGS000856
(T2D_LiverLipids)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.35 [1.22, 1.51] — — PC1-10 —
PPM002364 PGS000856
(T2D_LiverLipids)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.01 [0.94, 1.08] — — PC1-10 —
PPM002366 PGS000856
(T2D_LiverLipids)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.02 [0.95, 1.09] — — PC1-10 —
PPM002367 PGS000856
(T2D_LiverLipids)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 0.95 [0.9, 1.01] — — PC1-10 —
PPM002365 PGS000856
(T2D_LiverLipids)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 0.97 [0.91, 1.05] — — PC1-10 —
PPM002368 PGS000857
(T2D_Obesity)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.07 [0.97, 1.19] — — PC1-10 —
PPM002369 PGS000857
(T2D_Obesity)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.08 [1.01, 1.16] — — PC1-10 —
PPM002370 PGS000857
(T2D_Obesity)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.13 [1.05, 1.22] — — PC1-10 —
PPM002371 PGS000857
(T2D_Obesity)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.19 [1.11, 1.27] — — PC1-10 —
PPM002372 PGS000857
(T2D_Obesity)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.04 [0.99, 1.1] — — PC1-10 —
PPM002373 PGS000858
(T2D_Proinsulin)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 0.94 [0.85, 1.04] — — PC1-10 —
PPM002374 PGS000858
(T2D_Proinsulin)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.14 [1.06, 1.22] — — PC1-10 —
PPM002376 PGS000858
(T2D_Proinsulin)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 1.06 [0.99, 1.13] — — PC1-10 —
PPM002377 PGS000858
(T2D_Proinsulin)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.1 [1.04, 1.16] — — PC1-10 —
PPM002375 PGS000858
(T2D_Proinsulin)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 0.93 [0.87, 1.0] — — PC1-10 —
PPM002403 PGS000864
(T2D-gPRS)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.42 [1.28, 1.58] — — PC1-10 —
PPM002404 PGS000864
(T2D-gPRS)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 1.93 [1.79, 2.09] — — PC1-10 —
PPM002406 PGS000864
(T2D-gPRS)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 2.12 [1.96, 2.29] — — PC1-10 —
PPM002407 PGS000864
(T2D-gPRS)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 1.59 [1.5, 1.69] — — PC1-10 —
PPM002405 PGS000864
(T2D-gPRS)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.56 [1.45, 1.69] — — PC1-10 —
PPM002413 PGS000868
(T2D_221)
 PSS001092|
Ancestry Not Reported|
5,740 individuals
 PGP000214 |
Aksit MA et al. J Clin Endocrinol Metab (2020)
 Reported Trait: Cystic-fibrosis related diabetes HR: 1.285 — — PCs(1-4), site of recruitment —
PPM008968 PGS001294
(GBE_HC649)
 PSS004575|
African Ancestry|
6,497 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: TTE non-insulin-dependent diabetes mellitus — AUROC: 0.70052 [0.68094, 0.7201] R²: 0.10493
Incremental AUROC (full-covars): 0.00213
PGS R2 (no covariates): 0.00615
PGS AUROC (no covariates): 0.54526 [0.52378, 0.56673]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008969 PGS001294
(GBE_HC649)
 PSS004576|
East Asian Ancestry|
1,704 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: TTE non-insulin-dependent diabetes mellitus — AUROC: 0.75536 [0.71488, 0.79584] R²: 0.1242
Incremental AUROC (full-covars): 0.01544
PGS R2 (no covariates): 0.01604
PGS AUROC (no covariates): 0.5808 [0.52621, 0.63538]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008970 PGS001294
(GBE_HC649)
 PSS004577|
European Ancestry|
24,905 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: TTE non-insulin-dependent diabetes mellitus — AUROC: 0.72888 [0.71557, 0.7422] R²: 0.10344
Incremental AUROC (full-covars): 0.03534
PGS R2 (no covariates): 0.03413
PGS AUROC (no covariates): 0.63582 [0.62119, 0.65045]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008971 PGS001294
(GBE_HC649)
 PSS004578|
South Asian Ancestry|
7,831 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: TTE non-insulin-dependent diabetes mellitus — AUROC: 0.68707 [0.67293, 0.70121] R²: 0.11343
Incremental AUROC (full-covars): 0.01724
PGS R2 (no covariates): 0.02384
PGS AUROC (no covariates): 0.58532 [0.56986, 0.60078]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008972 PGS001294
(GBE_HC649)
 PSS004579|
European Ancestry|
67,425 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: TTE non-insulin-dependent diabetes mellitus — AUROC: 0.71038 [0.70256, 0.71821] R²: 0.08854
Incremental AUROC (full-covars): 0.04133
PGS R2 (no covariates): 0.03493
PGS AUROC (no covariates): 0.63323 [0.62453, 0.64194]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008973 PGS001295
(GBE_HC165)
 PSS004312|
African Ancestry|
6,497 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Type 2 diabetes — AUROC: 0.68145 [0.62426, 0.73864] R²: 0.04466
Incremental AUROC (full-covars): 0.00427
PGS R2 (no covariates): 0.00162
PGS AUROC (no covariates): 0.5359 [0.47698, 0.59482]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008974 PGS001295
(GBE_HC165)
 PSS004313|
East Asian Ancestry|
1,704 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Type 2 diabetes — AUROC: 0.83509 [0.71831, 0.95186] R²: 0.20575
Incremental AUROC (full-covars): -0.00085
PGS R2 (no covariates): 0.00265
PGS AUROC (no covariates): 0.56328 [0.47919, 0.64736]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008975 PGS001295
(GBE_HC165)
 PSS004314|
European Ancestry|
24,905 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Type 2 diabetes — AUROC: 0.69318 [0.65625, 0.73011] R²: 0.04603
Incremental AUROC (full-covars): 0.0115
PGS R2 (no covariates): 0.00675
PGS AUROC (no covariates): 0.58258 [0.54116, 0.62401]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008976 PGS001295
(GBE_HC165)
 PSS004315|
South Asian Ancestry|
7,831 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Type 2 diabetes — AUROC: 0.65806 [0.61856, 0.69756] R²: 0.0392
Incremental AUROC (full-covars): 0.01243
PGS R2 (no covariates): 0.00618
PGS AUROC (no covariates): 0.5613 [0.5184, 0.60421]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008977 PGS001295
(GBE_HC165)
 PSS004316|
European Ancestry|
67,425 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Type 2 diabetes — AUROC: 0.68247 [0.66155, 0.70338] R²: 0.03772
Incremental AUROC (full-covars): 0.01405
PGS R2 (no covariates): 0.00633
PGS AUROC (no covariates): 0.57592 [0.55208, 0.59975]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM005189 PGS001357
(T2D_AnnoPred_PRS)
 PSS003606|
European Ancestry|
178,138 individuals
 PGP000252 |
Ye Y et al. Circ Genom Precis Med (2021)
 Reported Trait: Type 2 diabetes — AUROC: 0.6446 — Age, sex, PCs(1-10) —
PPM009277 PGS001781
(T2D_PRSCS)
 PSS007684|
European Ancestry|
309,154 individuals
 PGP000261 |
Tamlander M et al. Commun Biol (2022)
 Reported Trait: Type 2 diabetes (incident and prevalent) OR: 1.59 [1.57, 1.61] AUROC: 0.758 [0.756, 0.761] — year of birth, sex, ten first principal components of Finnish ancestry, batch, genotyping array —
PPM009281 PGS001781
(T2D_PRSCS)
 PSS007685|
European Ancestry|
279,879 individuals
 PGP000261 |
Tamlander M et al. Commun Biol (2022)
 Reported Trait: Incident type 2 diabetes OR: 1.52 [1.49, 1.55] AUROC: 0.852 [0.849, 0.855] — year of birth, sex, ten first principal components of Finnish ancestry, batch, genotyping array —
PPM009283 PGS001781
(T2D_PRSCS)
 PSS007691|
European Ancestry|
328,115 individuals
 PGP000261 |
Tamlander M et al. Commun Biol (2022)
 Reported Trait: Incident type 2 diabetes OR: 1.51 [1.48, 1.54] AUROC: 0.669 [0.664, 0.675] — year of birth, sex —
PPM009285 PGS001781
(T2D_PRSCS)
 PSS007686|
European Ancestry|
309,154 individuals
 PGP000261 |
Tamlander M et al. Commun Biol (2022)
 Reported Trait: Prevalent type 2 diabetes OR: 1.59 [1.57, 1.61] AUROC: 0.81 [0.808, 0.813] — year of birth, sex, ten first principal components of Finnish ancestry, batch, genotyping array —
PPM009287 PGS001781
(T2D_PRSCS)
 PSS007692|
European Ancestry|
343,672 individuals
 PGP000261 |
Tamlander M et al. Commun Biol (2022)
 Reported Trait: Prevalent type 2 diabetes OR: 1.75 [1.72, 1.78] AUROC: 0.725 [0.721, 0.729] — year of birth, sex —
PPM009279 PGS001781
(T2D_PRSCS)
 PSS007690|
European Ancestry|
343,672 individuals
 PGP000261 |
Tamlander M et al. Commun Biol (2022)
 Reported Trait: Type 2 diabetes (incident and prevalent) OR: 1.68 [1.65, 1.7] AUROC: 0.708 [0.705, 0.711] — year of birth, sex —
PPM009444 PGS001818
(portability-PLR_250.2)
 PSS009288|
European Ancestry|
19,931 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.1246 [0.1109, 0.1382] sex, age, birth date, deprivation index, 16 PCs —
PPM009445 PGS001818
(portability-PLR_250.2)
 PSS009062|
European Ancestry|
4,121 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.0862 [0.0557, 0.1165] sex, age, birth date, deprivation index, 16 PCs —
PPM009447 PGS001818
(portability-PLR_250.2)
 PSS008392|
Greater Middle Eastern Ancestry|
1,197 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.1735 [0.1176, 0.2284] sex, age, birth date, deprivation index, 16 PCs —
PPM009448 PGS001818
(portability-PLR_250.2)
 PSS008170|
South Asian Ancestry|
6,312 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.1556 [0.1314, 0.1796] sex, age, birth date, deprivation index, 16 PCs —
PPM009449 PGS001818
(portability-PLR_250.2)
 PSS007957|
East Asian Ancestry|
1,808 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.0665 [0.0202, 0.1125] sex, age, birth date, deprivation index, 16 PCs —
PPM009450 PGS001818
(portability-PLR_250.2)
 PSS007738|
African Ancestry|
2,476 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.0956 [0.0562, 0.1346] sex, age, birth date, deprivation index, 16 PCs —
PPM009451 PGS001818
(portability-PLR_250.2)
 PSS008841|
African Ancestry|
3,896 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.0522 [0.0208, 0.0836] sex, age, birth date, deprivation index, 16 PCs —
PPM009446 PGS001818
(portability-PLR_250.2)
 PSS008616|
European Ancestry|
6,646 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.108 [0.0842, 0.1317] sex, age, birth date, deprivation index, 16 PCs —
PPM011082 PGS002026
(portability-ldpred2_250.2)
 PSS009288|
European Ancestry|
19,931 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.1304 [0.1168, 0.1441] sex, age, birth date, deprivation index, 16 PCs —
PPM011083 PGS002026
(portability-ldpred2_250.2)
 PSS009062|
European Ancestry|
4,121 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.0862 [0.0558, 0.1165] sex, age, birth date, deprivation index, 16 PCs —
PPM011084 PGS002026
(portability-ldpred2_250.2)
 PSS008616|
European Ancestry|
6,646 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.1134 [0.0896, 0.1371] sex, age, birth date, deprivation index, 16 PCs —
PPM011085 PGS002026
(portability-ldpred2_250.2)
 PSS008392|
Greater Middle Eastern Ancestry|
1,197 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.1764 [0.1205, 0.2312] sex, age, birth date, deprivation index, 16 PCs —
PPM011087 PGS002026
(portability-ldpred2_250.2)
 PSS007957|
East Asian Ancestry|
1,808 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.0786 [0.0324, 0.1246] sex, age, birth date, deprivation index, 16 PCs —
PPM011088 PGS002026
(portability-ldpred2_250.2)
 PSS007738|
African Ancestry|
2,476 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.1001 [0.0607, 0.1391] sex, age, birth date, deprivation index, 16 PCs —
PPM011089 PGS002026
(portability-ldpred2_250.2)
 PSS008841|
African Ancestry|
3,896 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.0806 [0.0493, 0.1118] sex, age, birth date, deprivation index, 16 PCs —
PPM011086 PGS002026
(portability-ldpred2_250.2)
 PSS008170|
South Asian Ancestry|
6,312 individuals
 PGP000263 |
Privé F et al. Am J Hum Genet (2022)
 Reported Trait: Type 2 diabetes — — Partial Correlation (partial-r): 0.158 [0.1338, 0.182] sex, age, birth date, deprivation index, 16 PCs —
PPM012733 PGS002243
(ldpred_t2d)
 PSS009522|
European Ancestry|
258,402 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.58 [1.56, 1.6] — — age, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012737 PGS002243
(ldpred_t2d)
 PSS009518|
European Ancestry|
110,597 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.55 [1.51, 1.59] — — age, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012741 PGS002243
(ldpred_t2d)
 PSS009514|
East Asian Ancestry|
178,726 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.37 [1.36, 1.39] — — age, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012745 PGS002243
(ldpred_t2d)
 PSS009526|
European Ancestry|
69,422 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.64 [1.6, 1.69] — — birth year, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012749 PGS002243
(ldpred_t2d)
 PSS009534|
European Ancestry|
25,696 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.46 [1.41, 1.51] — — age, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012753 PGS002243
(ldpred_t2d)
 PSS009530|
African Ancestry|
1,535 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.24 [1.09, 1.42] — — age, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012757 PGS002243
(ldpred_t2d)
 PSS009542|
European Ancestry|
343,676 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.78 [1.75, 1.81] — — age, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012762 PGS002243
(ldpred_t2d)
 PSS009538|
African Ancestry|
7,618 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.46 [1.32, 1.62] — — age, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012767 PGS002243
(ldpred_t2d)
 PSS009546|
South Asian Ancestry|
7,628 individuals
 PGP000271 |
Mars N et al. Cell Genom (2022)
 Reported Trait: Type 2 diabetes OR: 1.66 [1.55, 1.79] — — age, sex, 10 PCs (+/- dataset-specific technical covariates) —
PPM012949 PGS002277
(pPS_Insulin_secretion_1)
 PSS009629|
South Asian Ancestry|
5,806 individuals
 PGP000305 |
Siddiqui MK et al. Diabetologia (2022)
 Reported Trait: Age at diagnosis (overweight BMI) β: 32.68 (20.7) — R²: 0.0097 — —
PPM012950 PGS002277
(pPS_Insulin_secretion_1)
 PSS009629|
South Asian Ancestry|
5,806 individuals
 PGP000305 |
Siddiqui MK et al. Diabetologia (2022)
 Reported Trait: Age at diagnosis (obese BMI) β: 18.9 (10.76) — R²: 0.0036 — —
PPM012947 PGS002277
(pPS_Insulin_secretion_1)
 PSS009629|
South Asian Ancestry|
5,806 individuals
 PGP000305 |
Siddiqui MK et al. Diabetologia (2022)
 Reported Trait: Age at diagnosis — — Z: 5.2 — Z-score p-value < 0.0001
PPM012948 PGS002277
(pPS_Insulin_secretion_1)
 PSS009629|
South Asian Ancestry|
5,806 individuals
 PGP000305 |
Siddiqui MK et al. Diabetologia (2022)
 Reported Trait: Age at diagnosis (normal BMI) β: 37.31 (16.7) — R²: 0.012 — —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS009288 — — 19,931 individuals — European UK (+ Ireland) UKB —
PSS008392 — — 1,197 individuals — Greater Middle Eastern (Middle Eastern, North African or Persian) Iran (Middle East) UKB —
PSS009514 — —
[
  • 40,121 cases
  • , 138,605 controls
]
 — East Asian
(Japanese)		 — BBJ —
PSS009518 — —
[
  • 7,066 cases
  • , 103,531 controls
]
 — European
(Estonian)		 — EB —
PSS003606 — —
[
  • 4,659 cases
  • , 173,479 controls
]
 Mean = 56.81 years European — UKB —
PSS009522 — —
[
  • 37,001 cases
  • , 221,401 controls
]
 — European
(Finnish)		 — FinnGen —
PSS000042 T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications —
[
  • 118 cases
  • , 702 controls
]
,
38.8 % Male samples
 — African American or Afro-Caribbean — CARDIA —
PSS000043 T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications —
[
  • 97 cases
  • , 1,553 controls
]
,
46.5 % Male samples
 — European — CARDIA —
PSS000044 T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications —
[
  • 446 cases
  • , 3,025 controls
]
,
46.6 % Male samples
 — European — FOS —
PSS009526 — —
[
  • 5,228 cases
  • , 64,194 controls
]
 — European Norwegian HUNT —
PSS009629 — — 5,806 individuals — South Asian
(Indian)		 — INSPIRED Dr. Mohan’s Diabetes Specialities Centre (INSPIRED - DMDSC)
PSS004312 — —
[
  • 89 cases
  • , 6,408 controls
]
 — African unspecified — UKB —
PSS004313 — —
[
  • 16 cases
  • , 1,688 controls
]
 — East Asian — UKB —
PSS004314 — —
[
  • 180 cases
  • , 24,725 controls
]
 — European non-white British ancestry UKB —
PSS004315 — —
[
  • 171 cases
  • , 7,660 controls
]
 — South Asian — UKB —
PSS004316 — —
[
  • 581 cases
  • , 66,844 controls
]
 — European white British ancestry UKB Testing cohort (heldout set)
PSS009534 — —
[
  • 5,182 cases
  • , 20,514 controls
]
 — European — MGBB —
PSS009062 — — 4,121 individuals — European Poland (NE Europe) UKB —
PSS004575 — —
[
  • 806 cases
  • , 5,691 controls
]
 — African unspecified — UKB —
PSS004576 — —
[
  • 106 cases
  • , 1,598 controls
]
 — East Asian — UKB —
PSS004577 — —
[
  • 1,354 cases
  • , 23,551 controls
]
 — European non-white British ancestry UKB —
PSS004578 — —
[
  • 1,637 cases
  • , 6,194 controls
]
 — South Asian — UKB —
PSS004579 — —
[
  • 4,071 cases
  • , 63,354 controls
]
 — European white British ancestry UKB Testing cohort (heldout set)
PSS008170 — — 6,312 individuals — South Asian India (South Asia) UKB —
PSS009542 — —
[
  • 13,616 cases
  • , 330,060 controls
]
 — European British UKB —
PSS009538 — —
[
  • 691 cases
  • , 6,927 controls
]
 — African unspecified — UKB —
PSS000054 Prevalent T2D status was defined using self-reported medical history and medication —
[
  • 13,480 cases
  • , 311,390 controls
]
 — European — UKB —
PSS009546 — —
[
  • 1,120 cases
  • , 6,508 controls
]
 — South Asian — UKB —
PSS001084 Moderate Age-Related Diabetes (MARD) vs. controls —
[
  • 2,853 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001085 Moderate Obesity-related Diabetes (MOD) vs. controls —
[
  • 1,372 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001086 Severe Autoimmune Diabetes (SAID) vs. controls —
[
  • 450 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001087 Severe Insulin-Deficient Diabetes (SIDD) vs. controls —
[
  • 1,186 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001088 Severe Insulin-Resistant Diabetes (SIRD) vs. controls —
[
  • 1,125 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001044 Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes, and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the BMBB cohort T2D diabetes status was defined from algorithms extracted from electronic medical record (EMR) and includes family history of T2D as an exclusion criteria. For T2D cases, BMBB defined medications using unique RxNorm codes at an ingredient level and defined laboratory tests using the logical observations identifiers names and codes (LOINC) standard (https://www.phekb.org/phenotype/type-2-diabetes-mellitus). BioMe included all patients with ICD-9-CM codes of 250.x0 or 250.x2, except for codes 250.10 and 250.12 (indicative of T2D with ketoacidosis, a condition also closely associated with T1D), patients on T2D medications and/or insulin at any time, and all patients with abnormal glucose (>200 mg/dl) or hemoglobin A1c (HbA1c; ≥6.5%) laboratory test results. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. For the WHI cohort, T2D was documented at baseline by self-report in which each woman was asked whether she had ever been told that she had “sugar diabetes” by her physician. Incident diabetes during follow-up was documented by self-report at each semi-annual contact, when participants were asked, “Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?” Choices included “pills for diabetes” and “insulin shots for diabetes.”. For the ARIC cohort prevalent type 2 diabetes was defined at the baseline examination as fasting (≥8 h) blood glucose ≥126 mg/dL, or nonfasting glucose ≥200 mg/dL, self-report physician diagnosis of diabetes or “sugar in the blood,” or current medication use for diabetes within the last two weeks. For the CARDIA cohort, T2D was determined at last visit based on a combination of measured fasting glucose levels (≥7.0 mmol/L and ≥126 mg/dL) at examination years 0, 7, 10, 15, 20, or 25; self-report of oral hypoglycemic medications or insulin at years 0, 7, 10, 15, 20, or 25; a 2-h postload glucose ≥11.1 mmol/L (≥200 mg/dL) during a 75-g oral glucose tolerance test at years 10, 20, and 25; or an HbA1c ≥6.5% at years 20 and 25. —
[
  • 5,972 cases
  • , 9,637 controls
]
 — African American or Afro-Caribbean — ARIC, BioMe, CARDIA, MEC, WHI Possible sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Dafr.
PSS001045 Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the BMBB cohort T2D diabetes status was defined from algorithms extracted from electronic medical record (EMR) and includes family history of T2D as an exclusion criteria. For T2D cases, BMBB defined medications using unique RxNorm codes at an ingredient level and defined laboratory tests using the logical observations identifiers names and codes (LOINC) standard (https://www.phekb.org/phenotype/type-2-diabetes-mellitus). BioMe included all patients with ICD-9-CM codes of 250.x0 or 250.x2, except for codes 250.10 and 250.12 (indicative of T2D with ketoacidosis, a condition also closely associated with T1D), patients on T2D medications and/or insulin at any time, and all patients with abnormal glucose (>200 mg/dl) or hemoglobin A1c (HbA1c; ≥6.5%) laboratory test results. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. For the WHI cohort, T2D was documented at baseline by self-report in which each woman was asked whether she had ever been told that she had “sugar diabetes” by her physician. Incident diabetes during follow-up was documented by self-report at each semi-annual contact, when participants were asked, “Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?” Choices included “pills for diabetes” and “insulin shots for diabetes.”. —
[
  • 2,004 cases
  • , 2,572 controls
]
 — Asian unspecified — BioMe, MEC, WHI Possible sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Dasn.
PSS001046 Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the UKB cohort, T2D cases were defined by an ICD-10 code of E11.X or a self-reported diagnosis in an interview with a trained nurse. —
[
  • 19,786 cases
  • , 403,943 controls
]
 — European — UKB Possible significant sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Deur
PSS000017 Type 2 diabetes ascertainment was based on self-report in an interview with a trained nurse or an ICD-10 code of E11.X in hospitalization records. —
[
  • 5,853 cases
  • , 283,125 controls
]
 — European — UKB UKB Phase 2
PSS001047 Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the BMBB cohort T2D diabetes status was defined from algorithms extracted from electronic medical record (EMR) and includes family history of T2D as an exclusion criteria. For T2D cases, BMBB defined medications using unique RxNorm codes at an ingredient level and defined laboratory tests using the logical observations identifiers names and codes (LOINC) standard (https://www.phekb.org/phenotype/type-2-diabetes-mellitus). BioMe included all patients with ICD-9-CM codes of 250.x0 or 250.x2, except for codes 250.10 and 250.12 (indicative of T2D with ketoacidosis, a condition also closely associated with T1D), patients on T2D medications and/or insulin at any time, and all patients with abnormal glucose (>200 mg/dl) or hemoglobin A1c (HbA1c; ≥6.5%) laboratory test results. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. For the WHI cohort, T2D was documented at baseline by self-report in which each woman was asked whether she had ever been told that she had “sugar diabetes” by her physician. Incident diabetes during follow-up was documented by self-report at each semi-annual contact, when participants were asked, “Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?” Choices included “pills for diabetes” and “insulin shots for diabetes.”. For the SOL cohort, T2D cases were defined as those with fasting time >8 h and fasting glucose levels ≥126 mg/dL, fasting ≤8 h and fasting glucose ≥200 mg/dL, post–oral glucose tolerance test glucose ≥200 mg/dL, HbA1c ≥6.5% (48 mmol/mol), or on current treatment with antihyperglycemia medications. —
[
  • 4,137 cases
  • , 16,349 controls
]
 — Hispanic or Latin American — BioMe, MEC, SOL, WHI Possible sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Dhis.
PSS001048 Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individualswith (1) a T2D diagnosis by a physician/medical professional and use of medication for treat-mentofdiabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. —
[
  • 1,534 cases
  • , 2,017 controls
]
 — Oceanian
(Native Hawaiian)		 — MEC —
PSS008841 — — 3,896 individuals — African unspecified Nigeria (West Africa) UKB —
PSS000754 — — 87,413 individuals — European — UKB —
PSS000755 — — 87,413 individuals — European — UKB —
PSS000756 ICD-10 E11.0 - E11.9 —
[
  • 17,519 cases
  • , 117,781 controls
]
 — European
(Finnish)		 — FinnGen —
PSS000232 Individuals with T2D were defined as those with fasting time >8 h and fasting glucose levels ≥126 mg/dL, fasting ≤8 h and fasting glucose ≥200 mg/dL, post–oral glucose tolerance test glucose ≥200 mg/dL, HbA1c ≥6.5% (48 mmol/mol), or on current treatment with antihyperglycemia medications. —
[
  • 2,499 cases
  • , 5,247 controls
]
,
39.65 % Male samples
 — Hispanic or Latin American
(Central American, Cuban, Dominican, Mexican, Puerto Rican, South American)		 Ancestry groups were defined based on a combination of self-identified Hispanic/Latino background and genetic similarity HCHS, SOL —
PSS001092 All individuals had cystic fibrosis with either 2 severe CFTR mutations and/or clinically diagnosed exocrine pancreatic insufficiency. Cases are individuals with cystic fibrosis related diabetes (CFRD).Phenotypes were obtained from extracted medical charts and CF Foundation Patient Registry through 2011. CFRD was defined by clinician diagnosis of diabetes plus insulin treatment for at least 1 year. The onset of CFRD was defined as the date at which insulin was started, if it was subsequently continued for at least 1 year. In approximately 50% of the participants, independent laboratory data (such as oral glucose tolerance test or hemoglobin A1c) were able to independently confirm the diagnosis of CFRD. Diabetes data were censored at the last clinic visit or date of solid organ transplant. —
[
  • 1,341 cases
  • , 4,399 controls
]
,
47.04 % Male samples
 Mean = 20.0 years Not reported — CGS, CWRU, FrGMC, JHU, UNC —
PSS007957 — — 1,808 individuals — East Asian China (East Asia) UKB —
PSS009530 — —
[
  • 660 cases
  • , 875 controls
]
 — African American or Afro-Caribbean — MGBB —
PSS000869 CALIBER rule-based phenotyping algorithms (https://github.com/spiros/chronological-map-phenotypes#diabetes) Median = 6.9 years
[
  • 27 cases
  • , 3,060 controls
]
,
51.0 % Male samples
 Median = 44.0 years
IQR = [30.5, 54.7] years		 European — INTERVAL —
PSS000025 Incident cases of Type 2 Diabetes in 5.63 years follow-up —
[
  • 302 cases
  • , 5,978 controls
]
,
55.0 % Male samples
 — European
(Estonian)		 — EB —
PSS008616 — — 6,646 individuals — European Italy (South Europe) UKB —
PSS007684 Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 8/9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2019, whichever came first. Median = 13.0 years
IQR = [7.5, 19.7] years
[
  • 44,266 cases
  • , 264,888 controls
]
,
43.8 % Male samples
 Mean (Age At Baseline) = 53.2 years
Sd = 17.4 years		 European
(Finnish)		 — FinnGen —
PSS007685 Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 8/9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2019, whichever came first. —
[
  • 14,991 cases
  • , 264,888 controls
]
,
42.9 % Male samples
 Mean (Age At Baseline) = 51.8 years
Sd = 17.4 years		 European
(Finnish)		 — FinnGen —
PSS007686 Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 8/9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2019, whichever came first. —
[
  • 29,275 cases
  • , 279,879 controls
]
,
43.8 % Male samples
 Mean (Age At Baseline) = 53.2 years
Sd = 17.4 years		 European
(Finnish)		 — FinnGen —
PSS007690 Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the censoring date of hospital inpatient data (UK Biobank; English hospital inpatient records up to May 2020, Scottish up to November 2016, Welsh up to March 2016), whichever came first. Median = 10.4 years
IQR = [8.3, 11.3] years
[
  • 24,192 cases
  • , 319,480 controls
]
,
46.3 % Male samples
 Mean (Age At Baseline) = 57.4 years
Sd = 8.0 years		 European
(British)		 UK Biobank participants with non-British ancestry were excluded based on genetically inferred ancestry. UKB —
PSS007691 Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the censoring date of hospital inpatient data (UK Biobank; English hospital inpatient records up to May 2020, Scottish up to November 2016, Welsh up to March 2016), whichever came first. —
[
  • 8,635 cases
  • , 319,480 controls
]
,
45.5 % Male samples
 Mean (Age At Baseline) = 57.2 years
Sd = 8.0 years		 European
(British)		 UK Biobank participants with non-British ancestry were excluded based on genetically inferred ancestry. UKB —
PSS001117 T2D cases were defined as having an ICD-10 code of E11.X or having self-reported T2D in the in- terview. Only cases in which the individuals did not have T2D during the first assessment visit period (2006–2010) but were subsequently fol- lowed up for incident T2D events were considered. Median = 3.58 years
[
  • 1,281 cases
  • , 66,948 controls
]
,
47.81 % Male samples
 — European — UKB —
PSS007692 Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the censoring date of hospital inpatient data (UK Biobank; English hospital inpatient records up to May 2020, Scottish up to November 2016, Welsh up to March 2016), whichever came first. —
[
  • 15,557 cases
  • , 328,115 controls
]
,
46.3 % Male samples
 Mean (Age At Baseline) = 57.4 years
Sd = 8.0 years		 European
(British)		 UK Biobank participants with non-British ancestry were excluded based on genetically inferred ancestry. UKB —
PSS000441 National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. —
[
  • 1,346 cases
  • , 19,684 controls
]
,
47.3 % Male samples
 Mean (Age At Baseline) = 48.0 years European
(Finnish)		 — FINRISK FINRISK surveys from 1992, 1997, 2002 and 2007
PSS007738 — — 2,476 individuals — African American or Afro-Caribbean Carribean UKB —
PSS000448 National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. —
[
  • 17,519 cases
  • , 117,781 controls
]
,
43.7 % Male samples
 Mean (Age At Baseline) = 59.2 years
Sd = 16.6 years		 European
(Finnish)		 — FinnGen —